Serum levels of microRNAs in patients with heart failure

Abstract

AimsDiagnosis and risk stratification of patients with heart failure remain a challenge. The small non-coding RNAs known as microRNAs regulate gene expression and seem to play an important role in the pathogenesis of heart failure. In the current study, we aim to characterize the levels of microRNAs in the sera of chronic systolic heart failure patients vs. controls and assess the possible correlation between elevation in the levels of specific microRNAs and clinical prognostic parameters in heart failure patients. Methods and resultsThe levels of 186 microRNAs were measured in the sera of 30 stable chronic systolic heart failure patients and 30 controls using quantitative reverse transcription -polymerase chain reaction (qRT -PCR). The differences in micro-RNA levels between the two groups were characterized, and a score, based on the levels of four specific microRNAs with the most significant increase in the heart failure group (miR-423-5p, miR-320a, miR-22, and miR-92b), was defined. The score was used to discriminate heart failure patients from controls with a sensitivity and specificity of 90%. Moreover, in the heart failure group, there was a significant association between the score and important clinical prognostic parameters such as elevated serum natriuretic peptide levels, a wide QRS, and dilatation of the left ventricle and left atrium (r ¼ 0.63, P ¼ 3e-4; P ¼ 0.009; P ¼ 0.03; and P ¼ 0.01, respectively). ConclusionsElevated serum levels of specific microRNAs: miR-423-5p, miR-320a, miR-22, and miR-92b, identify systolic heart failure patients and correlate with important clinical prognostic parameters.--

Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers

“…Increases in circulating miRNAs upon cell damage have been detected by RT-PCR-based approaches for liver, brain, and skeletal muscle (5), as well as heart (19,46 instances miRNAs even performed better than established protein biomarkers (5). Our analysis indicated that heart-specific myomirs performed similar to the highly sensitive cTnI assay, but we were unable to verify the utility of any recently proposed miRNA biomarker for HF (18,(20)(21)(22). Considering that sRNAseq experiments capture a wide spectrum of miRNAs as well as fragments of other classes of RNAs, and can be performed with low ng quantities of total RNA recoverable from 250 μL plasma or serum, this approach holds great potential for future RNA biomarker discovery.…”

“…S1) were shown to contribute to muscle or myocardial function (8, 9). miRNAs and other classes of RNA have been profiled in failing human myocardium (10)(11)(12)(13)(14)(15)(16)(17), and a selected subset was also investigated as circulating biomarkers in HF (18)(19)(20)(21)(22)(23)(24). However, in these studies heart tissue and circulating miRNA abundance changes were not acquired simultaneously to correlate changes in tissue versus circulating miRNA composition.…”

MicroRNA-21 regulation of the progression of viral myocarditis to dilated cardiomyopathy

“…Furthermore, genetic studies have identified distinct roles for specific miRNAs during cardiogenesis, cardiac hypertrophy and electrical conduction (8,9). This led the present study to hypothesize that miRNAs may be critical in the progression of VMC to DCM.…”

MicroRNA and Its Role in Cardiovascular Disease

“…miR-1/21/22/23/29/122/130/195/199/320a/423-5p/499/622 levels were found to be overexpressed in heart failure patients. Particularly increased level of miR-423-5p was well correlated with heart failure in different studies [53] [57]. Similarly level of miR-122 and miR-370 were positively correlated with total cholesterol, Triglycerides and LDL cholesterol (LDL C) and coronary artery disease (CAD) progression [71].…”

“…Study by Goren et al [53] found that level of specific miRNAs like miR-423-5p, miR320a, miR-22 and miR-92b are found to be elevated in patient with systolic heart failure. Further study by Devaux et al [54] revealed that panels of 4 miRNAs namely miR-16, miR-27a, miR-101, and miR-150 are associated with improved prediction of left ventricular contractility six months after acute myocardial infarction (AMI).…”